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There is increasing interest in the integration of patient-reported outcomes (PROs) into health 
care research and clinical practice for the benefit of patients with end stage renal disease 
receiving haemodialysis (HD). In a research setting, PROs can be utilised as a patient-centred 
primary or secondary outcome in clinical studies. In routine care, PRO data may be used to 
support service delivery through benchmarking and audit, or to inform and enhance the care 
of the individual patient by improving patient-clinician communication. 
Despite evidence demonstrating the potential benefits of PROs and prioritisation of these 
outcomes by patients, their use in kidney disease remains limited. Whilst there are significant 
methodological and operational challenges for the widespread integration of PROs, there is 
now consensus that this area should be at the forefront of clinical research and 
implementation science. 
Here we discuss the current use of PROs for patients with end-stage renal disease receiving 
HD treatment and identify a roadmap for increasing the evidence base and introducing PROs 
into mainstream clinical practice. 
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Patients with end stage renal disease (ESRD) receiving haemodialysis (HD) often experience 
extensive physical symptoms (1, 2) , comparable to patients with advanced cancer (3, 4) and 
report poor health-related quality of life (HRQoL) (3, 5, 6). This impairment profile is 
associated with increased hospitalisation and mortality rates (7, 8). This population is highly 
heterogeneous, with varying underlying renal disease and presentation, often highlighting 
health disparities across different races, ethnicities and socioeconomic status (SES) (9). 
The success of HD management has traditionally been evaluated through biochemical 
dialysis-related targets (10) and mortality and survival rates (11). Similarly, in research 
settings, mortality is often used as a primary outcome measure, whereas outcomes such as 
pain, fatigue and dialysis-free time are not routinely captured, despite evidence that such 
outcomes are prioritised by patients over their own survival (3, 6, 10, 12, 13). One way to 
capture this information is using patient-reported outcome (PRO) data. Collection of PROs to 
provide the patient perspective on their health status/symptom burden offers a unique 
opportunity to identify and address some of the observed health disparities in the ESRD 
population, with consequent implications for health policy change. 
The FDA define a PRO as ‘any report coming from patients about a health condition and its 
treatment, without interpretation of the patient’s response by a clinician or anyone else’(14). 
These data can be gathered via validated instruments, commonly paper or electronic (ePRO) 
questionnaires. PRO tools may be ‘generic’, measuring HRQoL regardless of underlying 
disease process, or ‘disease-specific’, assessing the impact of a specific disease, such as 
kidney disease, and its associated symptoms and/or treatment.   
This paper will summarise key aspects of PRO use and implementation in HD research and 
routine care; highlighting recent developments, gaps in the field and future research priorities.  
PROs in HD research  
High quality aggregated PRO data collected from clinical trials can be used to inform 
labelling claims, health policy, and may direct individual care by allowing clinicians and 
patients to select the ‘best treatment’ from the patient’s perspective (15). 
Despite this, PRO collection in HD research remains uncommon (16). In a recent review of 
the Cochrane Database of Systematic Reviews and Clinicaltrials.gov for all studies involving 
prevalent patients on maintenance dialysis, quality of life was reported in just 9% of trials 
(17). 
Methodological research has highlighted deficiencies in PRO trial design and reporting; 
including renal trials (18). Where PROMs are collected, there is often a lack of detail and 
consistency regarding choice of measure; with different PROs being used to assess the same 
domain. This variability may prevent meaningful synthesis of results, hindering uptake in 
practice. Too often PROs are chosen and written into trial protocols based on familiarity and 
availability rather than assessed for relevance and appropriateness to the research question 
(19). 
Optimising the use of PROs in HD research 
The first step towards enhancing PRO capture in HD trials is to reach consensus on what 
domains should be measured (20, 21). This may be achieved through the development of 
Core Outcome Sets (COS). Led by the Core Outcome Measures in Effectiveness Trials 
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(COMET) initiative, COS development draws on consensus methodology, incorporating 
patient and public involvement, to agree on standardized outcomes to be measured and 
reported for all trials within a clinical specialty (20). This may lead to consistent collection of 
more meaningful patient-centered outcomes; reducing outcome reporting bias, aiding meta-
analysis and facilitating efficient use of precious health care resources (20, 22-26).  
The principal work on COS within nephrology is the SONG initiative (Standardized 
Outcomes in NephroloGy), formed to establish/implement core outcomes across the spectrum 
of chronic kidney disease, including HD (SONG-HD).(12, 27, 28) This initiative has 
identified a wide range of recommended outcomes, with patient involvement being a 
fundamental principle. However, further work is now required to identify robust PRO 
measures capable of capturing data across the spectrum of SONG-HD outcomes in a way that 
is non-burdensome for patients. Additionally, these measures should enable data collection 
across all patients receiving HD, including those with different language requirements, low 
educational attainment, cognitive impairment, or the critically unwell (27).  
PRO instrument selection 
Having identified outcomes of interest, it is important to spend time selecting the optimal 
measurement tool. The COnsensus-based Standards for the selection of health Measure 
Instruments (COSMIN) group provide guidelines to aid PROM selection based on a tool’s 
measurement properties, e.g. Validity, reliability, responsiveness and interpretability (Box 1) 
(23, 29). Recent systematic reviews have highlighted the need for comprehensive exploration 
of PROs used in HD (11, 30-34) and reviews of  PROs for fatigue (35)  anaemia  (36) and 
vascular access outcomes in maintenance HD trials (37) are currently taking place as part of 
the SONG-HD Initiative.  
Recent research has supported the KDQOL-36 and KDQOL-SF for use within the dialysis 
population (11, 38), with the longer KDQOL-SF appropriate for research use and the shorter 
KDQOL-36 of more use in routine clinical settings (Box 2). However, the authors concluded 
that further validation work is needed for all measures, particularly with English speakers 
(11). It is important to note that those measures currently recommended for use in HD do not 
appear to cover all SONG-HD outcomes. Clearly, work is still needed to identify/develop 
PROs to fill these gaps. 
PRO Trial design, implementation and reporting 
As with any trial outcome, PROs should be fully integrated into the design and 
implementation phases according to best-practice guidelines such as the SPIRIT (Standard 
Protocol Items: Recommendations for Interventional Trials) PRO extension. (39) This 
checklist details 16 items recommended for inclusion in a trial protocol where PROs are 
primary or secondary endpoint (39). Emerging evidence suggests that robust PRO protocol 
components aid high quality data collection and subsequent dissemination (40, 41).  
Unfortunately, however, PRO trial findings have been poorly reported to date, hindering 
uptake in practice (18, 41). To address this, the CONSORT (Consolidated Standards of 
Reporting Trials) PRO extension was developed in 2013 (42). Early evidence suggests that 
PRO reporting may be improved by journal endorsement and author use of CONSORT PRO 
(43). It is recommended that HD trialists utilise these best practice guidelines when 
incorporating PROs in their research. 
Implementing PROs in routine clinical HD practice  
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PROs have multiple potential uses (figure 1). In routine clinical settings PROs may aid 
patient-clinician and multidisciplinary team communication; enhance shared decision-making 
(44); and support symptom monitoring and management (45), allowing more personalised 
care. At an aggregate level, PRO data can be used for audit and benchmarking (46): for 
example, US Medicare & Medicaid Services mandate that HRQoL is assessed annually for 
patients receiving long-term dialysis (47). 
The International Society of Quality of Life Research (ISOQOL) ‘User’s Guide to 
Implementing Patient-Reported Outcomes Assessment in Clinical Practice’ (21, 48), 
identifies key pathway components for PROM integration into routine care:  
1. Defining the goals for PRO collection 
Given the potential multiple uses of PRO collection (figure 1), it is imperative that the goal 
for collection is clearly defined.  
Research suggests clinicians routinely underestimate patient symptoms (2, 49). There is 
increasing evidence that regular ePRO collection, both within and in-between clinics can be 
used to flag poor symptom control and deterioration in functional status. In oncology settings, 
this has led to improvements in HRQoL, enhanced patient-clinician communication, reduced 
hospitalisation and increased survival (45, 50-52). In Denmark, the generic PRO system 
AmbuFlex combines data collected remotely, with PRO-based automated decision algorithms 
and graphical overviews for symptom monitoring and decision making in nine diagnostic 
groups including CKD (53). There are many validated symptom assessment tools available 
for use with patients receiving HD (Box 2).  
PROs also have the potential to enhance shared-decision making and advance care planning. 
Findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS) suggest that 
patient-reported indicators on physical and mental functioning are prognostic markers (54) 
and that patients with lower PRO scores on the physical and mental components of the 
KDQOL-36 have higher mortality rates (55).  
2. Selecting Patients, Timing and setting of assessment: 
Appropriate timing and frequency of PRO assessment in HD is of great importance. A large 
proportion of patients receiving HD may exhibit cognitive impairment (56). However, there 
remains some debate about the exact level of impairment during different phases of the 
dialysis treatment cycle (56-58).  A recent consensus meeting involving patient 
representatives concluded that PROs should preferably not be recorded during dialysis (31), 
with PRO experts reflecting that responses given during a dialysis session may be sensitive to 
the current dialysis experience rather than ‘usual’ HRQoL. However, further qualitative work 
to elicit and clarify patient and clinician preferences on the timing of PROs completion is 
required (59). 
Consideration needs to be given to the setting where the PRO is completed. Patients may 
prefer to complete PROs at home or at the dialysis unit. Further research on where best to 
collect this information is required.  
Repeated assessments allow clinicians to track disease progression and inform changes in 
care (47). Management of patients receiving HD is complicated by multiple comorbidities, 
polypharmacy and variables associated with the dialysis treatment itself; consequently 
patients can experience dramatic changes in their health status (60). Moreover, patients  
usually dialyse at least 3 times per week for a number of hours, thus the additional patient 
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burden of completing PROs should be considered (61). Frequent collection of scores without 
associated intervention has been shown to be burdensome to patients, but data on the optimal 
frequency of collection of HRQoL information from patients with ESRD is lacking (61). 
PROs need to be sensitive enough to detect patient-important changes and undertaken often 
enough to allow accurate recall. A Danish feasibility study of PRO capture in routine 
practice, reported lower response rates from patients with CKD when compared with other 
patient groups (53); this needs further investigation. 
3. Determining which PRO to use in routine care: 
Recent systematic reviews have highlighted the current PROs most appropriate for use in HD 
settings (11, 30, 32, 33), including PROs which pertain to identified core outcomes such as 
fatigue (35).Based on a review of psychometric properties (38) Peipert & Hays suggested 
continued use of the KDQOL-36 for US dialysis center internal quality improvement activity. 
However, they state that the PROM could be modified by inclusion of Patient-Reported 
Outcomes Measurement Information System (PROMIS) general health items and fine tuning 
of the kidney disease-targeted scales (47). The National Institutes of Health PROMIS project 
uses item response theory (IRT) and computer adaptive technology (CAT) to capture global 
aspects of HRQoL and has been shown to be a potentially valuable tool to assess impact of 
chronic kidney disease in paediatric populations (62). CAT simplifies PRO completion by 
selecting questions with patient-specific relevance This process has a high level of reliability, 
and low burden, as patient responses are used to guide subsequent questions (63) 
Further research is required to identify/develop optimum PROs for routine use in HD 
settings. Cultural appropriateness and cross cultural reliability of such PROs should be 
assessed, with issues such as spirituality, which have different resonance for different ethnic 
groups (64) being considered. Key to this process is patient involvement in both item 
generation and selection (65). While pre-testing of PRO translations for comprehension, 
cultural relevance and acceptability is common in studies, research such as that conducted by 
Peipert et al, which examined differential item functioning between black and white patients 
on the KDQOL-36, is required before measures can be used to make clinical decisions with 
confidence across subgroups of patients (66).   
The International Consortium on Health Outcomes Measures (ICHOM) has recently 
published a data collection and reference guide for CKD (38). This includes the establishment 
of standard outcome sets for use in routine practice for patients receiving HD, along with 
recommended generic PRO measures. However, the generic measures chosen by the ICHOM 
CKD working group have not yet been formally validated in the HD population. 
4. Mode of administration and scoring: 
In 2015, as part of the Transforming Participation in Chronic Kidney Disease programme 
(TP-CKD) (67), a pilot study was undertaken by the UK Renal Registry involving the 
collection of patient symptom scores. Patients in 14 Renal Units were asked to complete the 
Integrated Patient Outcome Scale for Renal (IPOS-Renal) (68) and the EuroQol-5 
dimensions-5 levels (EQ-5D-5L) (69). Patients receiving HD were included in the sample. 
Whilst compliance was good, the use of paper questionnaires proved logistically complicated 
leading to a time lag between completion and feedback. Furthermore, clinical staff reported 
difficulty using and interpreting the survey results, requiring the organization of on-site 
workshops to support teams in interpretation and familiarization of the PRO data (1). 
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UK and Canadian studies have explored the feasibility of using ePROs in kidney disease, 
accessed by the patient using electronic devices (70-73). ePROs offer an avenue for the 
collection of remote PRO data in real-time, allowing health care professionals immediate 
access to important information to guide care (73). Pittman et al. (70) and Schick-Mazaroff & 
Molzahn (71-73) have explored the feasibility of ePRO collection, whilst demonstrating that 
it was feasible to collect ePRO data in dialysis environments, they found further research is 
needed to overcome measurement challenges, including aspects surrounding the 
responsiveness of the chosen PRO to changes in clinical condition, as well as practical issues 
such as IT security and cost.   
5. Interpretation and Feedback: 
The method of PRO data feedback will vary according to the goals of collection; for example, 
whether aggregate information is required for service improvement, or individual-level data 
needed to guide care (74). A recent realist synthesis identified a potential tension between 
these two goals and a need for further research on incorporating PRO data into the EHR, they 
questioned if the same PRO could be used for multiple purposes.(75) Individualised PROs 
that are useful for patient assessment may not be reliable as indicators of service quality and 
vice-versa. For multiplicity of use, all stakeholders should be effectively engaged in future 
PRO development (74, 76).  
Whatever the objective for collection, careful consideration is required to ensure that PRO 
scores are easily interpretable by all stakeholders. The information should be meaningful and 
actionable. How the data is visually displayed will impact its use, with studies suggesting that 
the preferred formats should be as user-friendly as possible (72), highlighting the importance 
of involving both patients and clinicians in design stages. Pertinent guidance on PRO data 
feedback is available from ISOQOL and the Patient-Centred Outcomes Research Institute 
(PCORI) (77), which highlights the importance of training in PRO administration and 
interpretation as a key methodological consideration.  
Increasingly PRO data collection is being undertaken by Renal Registries (1). Breckenridge 
et al. (31) report a consensus meeting (2015) held to discuss the routine collection of PRO 
data within European Renal Registries. Whilst agreeing that registries are an ideal way to 
collect PROs, they identified several challenges around implementation including resourcing, 
technological and information governance issues as well as maintaining trust in the data. 
They highlight the need for further research and collaboration to share best practice.  
6. Responding to issues raised: 
Tong et al. (2017) recognised that efforts to integrate PRO use in patients receiving HD may 
be hindered by issues associated with the range of co-morbidities and broader HRQoL 
outcomes experienced by this patient group, who are receiving a technically demanding 
treatment (78).  
Finkelstein & Finkelstein (79) discussed the challenge of capturing individual’s experiences 
of dialysis through twice-yearly paper PRO collection within US dialysis centres for 
performance monitoring and internal quality improvement (47). They identified issues that 
included actioning results and noted that clinicians sometimes had difficulty assisting with 
problems not directly associated with HD. They recommended that while PRO collection 
should be mandated, given a lack of hard data on optimum methods of implementation, 
innovative methods should be considered to incorporate PROs into the EHR of individual 
patients.   
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7. Evaluating the Impact of PRO intervention on practice: 
It is important that the impact of routine PRO collection is assessed to justify their collection 
and use (80). The financial and time resource costs associated with administration, 
interpretation and staff training (47), particularly with IT systems (73), need to be offset 
against the potential impact of the intervention. Finkelstein & Finkelstein argued that 
collection of PRO data using standardised questionnaires may not capture the unique 
experience of the individual (60) and it is recognised there are challenges and frustration 
associated in the uncovering of PROs where little or no effective intervention exists. Further 
study is required to assess whether PRO collection in such circumstances could have 
unintended negative consequences, such as promoting false hope or distress.  
 Future research 
Whilst SONG-HD has identified many outcomes that clearly matter to stakeholders (12, 27, 
28), they do not map easily to existing measures, so new instruments may be required, which 
efficiently capture all required domains in a non-burdensome way. Innovative means of PRO 
data capture are required. Platforms which can collect, collate and feedback PRO data, via the 
electronic health record /national renal registries, need further investigation and investment. 
Development of  digital systems using item banks and CAT algorithms could be one way of 
lessening the burden and allow PRO data collected at specific time points to be used for 
multiple purposes (63).  
It is important to capture the perspectives of the nephrology multidisciplinary team on 
feasibility, cost and patient acceptance of PROMs. Tong et al. have used qualitative 
methodology to elicit nephrologists’ perspectives on defining and applying PROs in HD (78, 
81). Clinicians identified the challenges around the heterogeneity of patient priorities and 
experiences, limitations of current clinical approaches and health-system level barriers, 
including cost and resource constraints. The authors acknowledged that not all clinicians 
agree that a patient-centred approach to care is better than a disease-orientated approach (78). 
Further work is required to ascertain if these findings are capable of broader transferability. 
In terms of overall generalisability, lifestyle outcomes that were given a high priority by 
patients and caregivers in the SONG-HD initiative were derived from international 
participants receiving both in-center and Home-HD (12, 27). However, there will be nuances 
in the implementation of PROs with sub groups of patients receiving HD. In the UK, satellite 
dialysis units may be run by providers independent of the National Health Service, this means 
local considerations need to be made, such as IT linkage facilities. As recognised by 
Zbroezek et al., different clinical environments will provide unique and potentially diverse 
challenges, therefore real-world testing is imperative (82).  
Conclusion 
Shared decision-making and the provision of patient-centred care is crucial for excellence in 
HD provision. The use of PROs in both research and routine clinical settings may facilitate 
this. However, successful implementation of PROs requires careful planning and evaluation, 
and data collection must fit into current research study designs and work flow patterns. 
Addressing issues required for effective implementation will require input and collaboration 
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Box 1: Overview of Measurement Properties (29) 
 




i.e. Can the measure yield the same results when repeated. 
Internal 
Consistency 
The degree of correlation between different items in the 
measure. 
Validity The extent to which the measure assesses what it claims to 
measure 




i.e. Does the measure cover all the important dimensions of the 
health condition being assessed, does the measure appear to 
assess what it intends to assess. 
Construct Validity i.e. Does the measure assess the intended outcome of interest, 




Subtypes of construct validity: 
Convergent validity – can two measures of an outcome that 
should be theoretically related, actually be observed to be 
related. 
Discriminant validity – can measures that are theoretically 
related be observed to be dissimilar. 
Responsiveness Can the measure detect change in an outcome over time. 
Interpretability The degree to which meaning can be assigned to the scores 















Box 2 – Examples of Renal specific PROs commonly used in HD settings 
Measure Description 
Kidney Disease 
Quality of life-36 
KDQOL-36 
A36-item HRQOL measure designed for patients undergoing dialysis, 
derived from the KDQOL-SF.  
3 specific dimensions: 
(i) signs and symptoms (ii) burden of kidney disease (iii) effects of kidney 
disease 
and a generic core derived from the SF-12 (physical and mental scales). 
Overall scores range from 0-100, with higher scores indicating better 
HRQOL (38) 
Kidney Disease 
Quality of life-SF 
KDQOL-SF 
An 80-item HRQOL measure designed for patients undergoing dialysis 
which includes the SF-36 as a generic core (physical and mental scales) 
supplemented with 8 kidney disease-targeted dimensions and 3 additional 
QOL dimensions. 




Scale – Renal 
IPOS-Renal 
 IPOS-Renal is a short measure (11 questions), combining the most 
common symptoms renal patients experience plus additional items from 
IPOS on concerns beyond symptoms, such as information needs, practical 







Modified ESAS to measure symptom burden in patients receiving dialysis. 
10 symptom-specific items, 10 visual analogue scales with a superimposed 
0-10 scale: anchor words ‘No’ at 0 and ‘Severe’ at 10. Total score range 0-




DSI is a 30-item symptom and prevalence assessment index for patients 
receiving haemodialysis. Overall scores for symptom burden and total 
symptom severity are calculated. Score range 0-150, with higher scores 




Figure 1: The multiple uses of PROs (first published in The BMJ Calvert et al 2019 87) 
 
 
 
 
 
 
